Lantern Pharma Launches AI Module PredictBBB.ai(TM) to Revolutionize Blood-Brain Barrier Permeability Predictions
TL;DR
Lantern Pharma's predictBBB.ai offers a competitive edge in drug development by accurately predicting BBB permeability, potentially accelerating oncology treatments to market.
predictBBB.ai utilizes Lantern Pharma's vast data lake and advanced AI to analyze small molecules' BBB permeability with high accuracy, sensitivity, and specificity.
By improving the prediction of BBB permeability, predictBBB.ai could significantly enhance the development of treatments for brain-related cancers, benefiting patients worldwide.
Lantern Pharma's AI module, predictBBB.ai, stands out by processing compounds in real time, marking a leap forward in oncology drug development technology.
Found this article helpful?
Share it with your network and spread the knowledge!
Lantern Pharma (NASDAQ: LTRN), a leader in AI-driven oncology drug development, has unveiled predictBBB.ai(TM), a groundbreaking public AI module designed to predict the blood-brain barrier (BBB) permeability of small molecules with unprecedented accuracy. This innovation boasts a 94% accuracy rate, 95% sensitivity, and 89% specificity, setting a new standard in pharmaceutical research and development. The platform is built upon billions of molecular data points from Lantern's proprietary data lake, offering a solution to the longstanding challenge that only 2–6% of small molecules can cross the BBB, a critical barrier in treating neurological diseases and cancers affecting the brain.
The significance of predictBBB.ai(TM) extends beyond its technical achievements. It ranks among the top performers on the Therapeutic Data Commons Leaderboard, thanks to its use of synthetic data augmentation and advanced molecular representation techniques that allow for real-time compound processing. This launch is timely, as the BBB technologies market is on a steep growth trajectory, projected to expand from $1.4 billion in 2023 to $9.85 billion by 2032. This growth underscores the clinical demand for innovative solutions that can navigate the complexities of the BBB, making predictBBB.ai(TM) a pivotal tool in the future of drug development.
For more details on this development, visit https://ibn.fm/pRgxt. Lantern Pharma's commitment to leveraging AI and machine learning in oncology drug discovery is evident in their proprietary RADR(R) platform, which utilizes over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms. This approach not only accelerates the development of their pipeline of therapies but also addresses billion-dollar challenges in oncology drug development, offering hope for more effective treatments for cancer patients worldwide.
Curated from InvestorBrandNetwork (IBN)
